keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sirpiglenastat (DRP-104) is a glutamine antagonist, a prodrug of DON, with antitumor activity that acts by inhibiting glutamine metabolism and stimulating the innate and adaptive immune system.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 313.00 | |
5 mg | In stock | $ 943.00 | |
10 mg | In stock | $ 1,650.00 | |
25 mg | In stock | $ 2,460.00 | |
50 mg | In stock | $ 3,320.00 | |
100 mg | In stock | $ 4,480.00 |
Description | Sirpiglenastat (DRP-104) is a glutamine antagonist, a prodrug of DON, with antitumor activity that acts by inhibiting glutamine metabolism and stimulating the innate and adaptive immune system. |
In vitro | Treatment with Sirpiglenastat (DRP-104) exhibits broad immune cell modulation effects, including an increase in T cells, NK cells, and macrophages. Sirpiglenastat also reduces the levels of pro-tumorigenic cytokines such as VEGF and KC (IL-8)[1]. |
In vivo | In CT26 bearing mice, treatment with Sirpiglenastat (DRP-104) at a dose of 0.5 mg/kg through subcutaneous injection once a day for 5 days results in a 90% inhibition of tumor growth by day 12, with a median survival of 36 days[1].Additionally, Sirpiglenastat treatment (0.5 mg/kg; s.c) significantly inhibits tumor growth in the H22 model[1]. |
Synonyms | DRP-104 |
Molecular Weight | 441.48 |
Formula | C22H27N5O5 |
CAS No. | 2079939-05-0 |
keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL(181.21 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sirpiglenastat 2079939-05-0 Proteases/Proteasome Glutaminase DRP-104 inhibitor inhibit